1. Home
  2. CISO vs CING Comparison

CISO vs CING Comparison

Compare CISO & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CISO Global Inc.

CISO

CISO Global Inc.

HOLD

Current Price

$0.46

Market Cap

24.5M

Sector

Technology

ML Signal

HOLD

CING

Cingulate Inc.

HOLD

Current Price

$4.16

Market Cap

26.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CISO
CING
Founded
2015
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.5M
26.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CISO
CING
Price
$0.46
$4.16
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$31.33
AVG Volume (30 Days)
817.2K
122.1K
Earning Date
11-13-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$27,743,266.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.30
$3.20
52 Week High
$3.84
$6.01

Technical Indicators

Market Signals
Indicator
CISO
CING
Relative Strength Index (RSI) 30.22 63.53
Support Level $0.46 $3.75
Resistance Level $0.60 $4.02
Average True Range (ATR) 0.06 0.23
MACD 0.01 0.07
Stochastic Oscillator 3.07 80.56

Price Performance

Historical Comparison
CISO
CING

About CISO CISO Global Inc.

CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.

Share on Social Networks: